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Abstract
FarnesoidXreceptor(FXR)isanuclearreceptorandakeyregulatoroflivercholesterolandtriglyceridehomeostasis.Scavenger
receptor class B type I (SR-BI) is critical for reverse cholesterol transport (RCT) by transporting high-density lipoprotein (HDL)
into liver. FXR induces SR-BI, however, the underlying molecular mechanism of this induction is not known. The current study
confirmed induction of SR-BI mRNA by activated FXR in mouse livers, a human hepatoma cell line, and primary human
hepatocytes. Genome-wide FXR binding analysis in mouse livers identified 4 putative FXR response elements in the form of
inverse repeat separated by one nucleotide (IR1) at the first intron and 1 IR1 at the downstream of the mouse Sr-bi gene. ChIP-
qPCR analysis revealed FXR binding to only the intronic IR1s, but not the downstream one. Luciferase assays and site-directed
mutagenesis further showed that 3 out of 4 IR1s were able to activate gene transcription. A 16-week high-fat diet (HFD)
feeding in miceincreased hepatic Sr-bi gene expression in a FXR-dependent manner. In addition,FXR bound to the 3 bona fide
IR1s in vivo, which was increased following HFD feeding. Serum total and HDL cholesterol levels were increased in FXR
knockout mice fed the HFD, compared to wild-type mice. In conclusion, the Sr-bi/SR-BI gene is confirmed as a FXR target gene
in both mice and humans,and at least in mice, induction of Sr-bi by FXR is via binding to intronic IR1s. This study suggests that
FXR may serve as a promising molecular target for increasing reverse cholesterol transport.
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Introduction
FXR (farnesoid X receptor, NR1H4) is a bile acid-activated
transcription factor and a member of the nuclear receptor
superfamily. Strongly expressed in the liver and intestine, FXR
has been shown to be the master transcriptional regulator not only
of the biosynthesis and enterohepatic circulation of bile acids, but
also of cholesterol and triglyceride homeostasis [1,2,3,4]. Disrup-
tion of the FXR gene in mice results in a variety of
pathophysiological conditions, including a proatherosclerotic lipid
profile with increased serum cholesterols and triglycerides [1],
cholestasis, non-alcoholic fatty liver diseases, cholesterol gallstone
disease, hepatocellular carcinoma, and intestinal inflammation
and tumors [5,6].
Scavenger receptor class B type I (SR-BI) is a cell surface
glycoprotein and was first cloned in 1994 as the receptor
mediating selective uptake of high-density lipoprotein (HDL)-
cholesterol into liver, adrenals, testes, and ovaries [7,8,9,10]. As a
HDL receptor, SR-BI is a key regulator in enhancing reverse
cholesterol transport (RCT) in the liver, and hepatic over-
expression of SR-BI can decrease plasma levels of HDL
cholesterol, which may have anti-atherosclerosis effects
[10,11,12]. One of the mechanisms by which FXR is involved
in regulating cholesterol and bile acid homeostasis is via
transcriptional regulation of target gene expression. FXR has
previously been shown to induce SR-BI expression [4,13,14].
However, the underlying molecular mechanism by which FXR
induces SR-BI expression is not fully defined. Therefore, the
purpose of the current study is to determine the molecular
mechanism by which FXR regulates SR-BI expression in human
and mouse models.
Results
Activation of FXR induced SR-BI expression in mouse
livers, primary human hepatocytes and human
hepatoma cell line, HepG2 cells
First, the induction of hepatic Sr-bi was determined in mice
treated with FXR natural and synthetic ligands, cholic acid (CA)
and GW4064, respectively, as well as by genetic over-expression of
FXR (FXR-Tg mice). The activation of FXR was first verified by
determining the mRNA expression of bona fide FXR targets
[15,16]. Strong induction of small heterodimer partner (Shp),
organic solute transporter b (Ostb), and bile salt export pump
(Bsep), as well as great suppression of cytochrome P450, family 7,
subfamily A, polypeptide 1 (Cyp7a1) and Na+/taurocholate
cotransporting polypeptide (Ntcp), were shown in livers of mice
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of FXR (Figure 1, Figure S1). The induction of Sr-bi was then
determined and results showed activation of FXR induced Sr-bi
mRNA 3.0, 3.5, and 2.8 fold with CA, GW4064 and transgenic
expression of FXR, respectively (Figure 1A, B). Furthermore, the
induction appears to be FXR-mediated because FXR-knockout
(KO) mice did not have increased Sr-bi expression following CA or
GW4064 treatment.
To further test whether SR-BI is a FXR target gene in humans,
the induction of SR-BI in primary human hepatocytes and in
HepG2 cells was determined. In primary human hepatocytes,
SHP mRNA levels were induced by increasing concentrations of
chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), and
lithocholic acid (LCA), but the SR-BI mRNA levels were induced
only by increasing concentrations of CDCA and DCA, but not
LCA (Figure 2A). In addition, FXR activation by GW4064 or
CDCA treatment increased mRNA levels of SR-BI in HepG2
cells, which are commonly used as a substitute for human
hepatocytes (Figure 2B).
FXR binds to multiple regions in the mouse Sr-bi gene
The mechanism of induction of SR-BI by FXR in humans has
been shown to be a result of direct binding of FXR to a direct
repeat separated by 8 nucleotides (DR8) response element in the
promoter of the SR-BI gene [14]. However, the mechanism of SR-
BI induction in mice is not known, and it is necessary to determine
species differences in order to use mouse models to study the
regulation of SR-BI in humans. According to the published ChIP-
seq (chromatin immunoprecipitation coupled with high-through-
put DNA sequencing) analysis [15,17], FXR does not bind to
promoter regions of the mouse Sr-bi gene. Instead, novel FXR
binding sites were indentified in three regions within the first
intron (A, B and C) and the downstream region (D) of the Sr-bi
gene (Figure 3A). Further analysis showed that all FXR binding
regions contained putative FXR response elements (FXRREs) in
the form of inverted repeats separated by one nucleotide (IR1)
(Figure 3B). Moreover, binding region C contained two IR1s
(Figure 3B). The sequence of these novel IR1s was shown to be
highly conserved in mice and rats, but not in humans (Figure 3B).
To validate FXR binding to the novel IR1s identified in the Sr-
bi gene, ChIP-qPCR (chromatin immunoprecipitation quantitative
real-time PCR) was performed on livers of mice treated with
vehicle or GW4064. In mice treated with vehicle, FXR bound to
regions B and C. In mice treated with GW4064, FXR binding
increased within all three of these regions in mouse livers
(Figure 4A). However, FXR did not bind to site D located
downstream of the Sr-bi gene in livers of either vehicle or GW4064
treated mice (Figure 4A).
Functional assessment of the novel FXR binding sites in
the Sr-bi gene by luciferase reporter gene assay and site-
directed mutagenesis assay
Luciferase reporter gene assays were used to determine whether
the three FXR binding sites (A, B and C) in the Sr-bi gene are
functional in enhancing transcriptional activity. Compared to the
vehicle control, all three binding sites in the first intron of the Sr-bi
gene (A, B and C) were effective in inducing luciferase activity 12,
9 and 13 fold, respectively (Figure 4B). The transcriptional
activations were greatly diminished, when the IR1 sequences were
mutated in binding sites A and B of the Sr-bi gene. The luciferase
gene expression was significantly decreased after mutation of the
first IR1 sequences alone or of both IR1 sequences in binding site
C. However, the transcriptional activation was not affected by
mutation of the second IR1 sequences alone in binding site C
(Figure 4B).
Serum cholesterol profiles and hepatic total cholesterol
levels were increased in FXR-KO mice
To further determine the physiological consequences of FXR
induction of Sr-bi on HDL transport into the liver, serum
cholesterol profiles and hepatic total cholesterol levels were
measured in FXR-KO and wild-type (WT) mice fed a control or
high-fat diet (HFD) for 16 weeks. Serum total cholesterol level
increased in FXR-KO mice when compared to WT mice
regardless of diet type (Figure 5A). Further analysis showed that
the increased serum cholesterol level in FXR-KO mice was due to
increase in HDL cholesterol but not in LDL/VLDL cholesterol
(Figure 5B). Even though the total hepatic cholesterol level
slightly increased in FXR-KO mice fed a control diet, the hepatic
cholesterol level did not significantly change between WT and
FXR-KO mice fed a HFD (Figure 5C).
Figure 1. Sr-bi transactivation is FXR dependent in mouse liver.
A, Induction of Sr-bi mRNA expression in the liver following treatment
with either 1% cholic acid (CA)-containing diet or GW4064 in WT and
FXR-KO mice as described in the Methods. Shp gene expression level
serves as a positive control to indicate FXR activation. An asterisk
indicates P,0.05 between vehicle and ligand treatment group. B, Fxr,
Shp and Sr-bi mRNA expression levels in liver of FXR-WT and FXR-Tg
mice. An asterisk means P,0.05 between FXR-WT and FXR-Tg group.
doi:10.1371/journal.pone.0035895.g001
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expression in WT mouse liver by direct binding of FXR to
multiple sites in the Sr-bi gene
FXR activation in liver by HFD feeding was evaluated in WT
and FXR-KO mice. HFD, administered for 16 weeks, induced the
mRNA levels of Fxr by 1.5 fold, Shp by 1.8 fold and Sr-bi by 1.6
fold in the livers of WT mice, but not in FXR-KO mice
(Figure 6A). Furthermore, ChIP-qPCR assays showed that HFD
treatment, similar to GW4064, increased the binding of FXR to
the three binding sites (A, B and C) in the first intron of the Sr-bi
gene (Figure 6B). However, FXR did not bind to the downstream
region (site D) of the Sr-bi gene by HFD treatment (Figure 6B).
Discussion
The present study showed that SR-BI mRNA was induced in a
FXR-dependent manner in mouse livers, primary human
hepatocytes and HepG2 cells. Our results suggest that FXR
Figure 2. FXR activation induces SR-BI gene expression in primary human hepatocytes and HepG2 cells. A, Primary human heptaocytes
were treated with 0.1% DMSO as a negative control or increasing concentrations of CDCA, DAC and LCA (10, 30 and 100 mM) for 48 hrs. The mRNA
levels of FXR, SHP, and SR-BI were determined by Q-PCR. An asterisk means P,0.05 between cholic acid treatment and control group. B, HepG2 cells
were treated with 0.1% DMSO as a negative control, 500 nM GW4064 or 100 mM CDCA for 24 hrs, respectively. The mRNA levels of FXR, SHP, and SR-
BI were determined by Q-PCR. An asterisk indicates P,0.05 between FXR ligand treatment and no treatment control group.
doi:10.1371/journal.pone.0035895.g002
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first intron of the Sr-bi gene. Moreover, the serum HDL level was
increased in FXR-KO mice when fed either a control or HFD.
Increased Sr-bi mRNA levels were shown to be FXR-dependent
under HFD feeding by direct binding of FXR to the first intron of
the Sr-bi gene, which indicates that FXR may enhance HDL
uptake into the liver via inducing Sr-bi gene transcription.
Activation of FXR has been demonstrated to regulate the
expression of many hepatic genes involved in lipid homeostasis,
including SR-BI [4]. Consistent with our findings (Figure 1, 2),
Sr-bi mRNA levels have been shown to increase in livers of
C57BL/6J mice but not in livers of FXR-KO mice upon LCA and
CA feeding [4,18,19]. However, a conflict result has been reported
that Sr-bi expression was reduced following administration of
CDCA or GW404764 (a FXR agonist) both in vivo and in vitro. The
authors further demonstrated that the decrease of Sr-bi was
mediated by the FXR/RXR-SHP-liver receptor homologue 1
(LRH-1) pathway [20]. These conflicting results may be due to the
different experimental models and/or ligands used.
The underlying molecular mechanisms of FXR in regulating
SR-BI and the role of SR-BI in FXR-mediated lipid homeostasis
are still not clear. Recently, a vast database of nuclear receptor
binding sites has been established with the development of
genome-wide discovery of transcription factor binding sites by
Figure 3. Novel FXR response elements, IR1s, in the first intron and downstream of the mouse Sr-bi gene. A, The novel four FXR binding
sites (A, B, C, and D) in the Sr-bi gene identified by ChIP-seq analysis. B, The novel IR1s (A, B, C-1
st, C-2
nd and D) identified at the first intron and
downstream of the Sr-bi gene are conserved within mouse and rat, but not human, Sr-bi/SR-BI gene. The novel IR1s are marked in the box.
doi:10.1371/journal.pone.0035895.g003
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array technology) and ChIP-seq techniques [21,22,23]. These data
have shown that transcription factors tend to bind to multiple sites
in the promoter and/or enhancer regions of target genes
[17,24,25,26]. Although our original ChIP-seq data did not show
FXR binding to the promoter region of Sr-bi (Figure 3A), we
found three FXR binding sites within the first intron of Sr-bi gene
(Figure 3A, B). Moreover, even though luciferase activity did not
correlate with the abundance of FXR binding, all three of these
novel response elements, which include IR1s, were demonstrated
functional (Figure 4). Site-directed mutagenesis results further
demonstrated that the IR1s in binding sites A and B, as well as the
first but not the second IR1 in binding site C are functional for
FXR regulation of Sr-bi gene expression. These results indicate
that activation of FXR could induce Sr-bi transcription by directly
binding to multiple IR1s located in Sr-bi gene. However, a recent
study showed that FXR up-regulated Sr-bi in mouse hepatocytes
through a FXR-pJNK-hepatocyte nuclear factor 4 a (HNF4 a)-
SR-BI pathway, which indicates FXR may regulate SR-BI in both
direct and indirect manners [13]. In addition to FXR, another
nuclear receptor, peroxisome proliferator-activated receptor a
(PPARa), can also increase Sr-bi expression in liver of rats [27].
Figure 4. FXR activates Sr-bi by binding to the IR1s within the first intron, but not the downstream region of the Sr-bi gene. A, ChIP-
qPCR assays showed binding of FXR to the intron (binding sites A, B, and C) but not the downstream region (binding sites D) of Sr-bi gene containing
the novel IR1s in mouse liver after treatment with GW4064. The relative intensity (fold) indicates fold increase over vehicle treatment. n=5 mice per
group. A pound sign indicates P,0.05 between binding site A and other binding sites. An asterisk means P,0.05 and double asterisks mean P,0.01
between vehicle and GW4064 treatment. B, Luciferase assay revealed that, upon FXR activation, the IR1s at the first intron of Sr-bi gene are functional
in enhancing gene transcription. The DNA constructs containing the novel FXR binding sites (IR1s) found in the first intron of Sr-bi gene and the DNA
constructs containing mutant corresponding novel IR1s were cloned into a pGL4-23 firefly luciferase vector and transfected into HepG2 cells as
indicated in the Methods. The cells were then treated with vehicle (0.1% DMSO) or 1 mM GW4064 for 36 hrs followed by evaluation of luciferase
activity. The white bar is for cells treated with vehicle and the black bar is for cells treated with 1 mM GW4064. The relative luciferase activity (fold)
indicates fold increase over empty vector by vehicle treatment. The fold induction of luciferase activity by these constructs with GW4064 treatment
compared to DMSO is indicated next to the black bars. Double asterisks indicate P,0.01 between vehicle and GW4064 treatment.
doi:10.1371/journal.pone.0035895.g004
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cells [28], which may represent another indirect mechanism of
FXR in induction of Sr-bi expression in human. However,
activation of PPARa in mouse livers by fibrates decreased hepatic
Sr-bi protein expression without changing Sr-bi mRNA levels. The
posttranscriptional regulatory effect of fibrates on murine hepatic
Sr-bi protein levels was further demonstrated PPARa dependent
using PPARa deficient mice [29]. These controversial results on
Sr-bi regulation by activation of PPARa may due to species-specific
differences.
Even though no IR1 was found in the human SR-BI gene
compared to the mouse gene (Figure 3B), our results still showed
that activating FXR increased SR-BI expression in primary
human hepatocytes and a human hepatoma cell line (Figure 2).
One recent study demonstrated that FXR directly activates SR-BI
gene transcription by binding to a DR8 motif in the promoter
region of the human SR-BI gene [14], which may help in
understanding the underlying molecular mechanisms of FXR in
regulating human SR-BI expression. Increasing studies also have
shown that a variety of nuclear receptors, including liver X
receptors (LXR), LRH-1, peroxisome proliferator-activated re-
ceptor c (PPARc), and HNF4a can stimulate hepatic SR-BI gene
expression in humans [30,31,32,33]. Thus, FXR may also
modulate SR-BI expression through regulating or interacting with
these nuclear receptors or signaling pathways. These data suggest
that activation of FXR could up-regulate hepatic SR-BI
transcription either directly or through coordinating the activity
of other nuclear receptors in both mouse and human livers.
Hepatic SR-BI has been shown to serve as a key mediator of
RCT by taking of HDL cholesterol to the liver [34]. A series of
studies using transgenic or recombinant adenovirus-mediated mice
showed that hepatic over-expression of SR-BI markedly reduces
atherosclerosis [10,11,35]. Furthermore, SR-BI KO mice have
higher HDL cholesterol in the circulation and enhanced
atherosclerosis development [36]. These results suggest that
hepatic SR-BI is critical in protecting against atherosclerosis
development. Our studies showed that, compared to WT mice,
FXR-KO mice had more serum total and HDL cholesterol
(Figure 5). Since SR-BI plays a key role in mediating selective
HDL cholesterol uptake in the liver, these results indicate that the
Figure 5. Cholesterol profile of wild type and FXR-KO mice fed the control or high fat-containing diet. Serum and liver lipids were
isolated from WT and FXR-KO mice treated with vehicle or high fat-containing diet (HFD) for 16 weeks. Serum total cholesterol (A), serum HDL and
LDL/VLDL cholesterol (B), as well as liver total cholesterol (C) were measured as described in the Methods. n=5–7 mice per group. An asterisk means
P,0.05 between WT and FXR-KO vehicle group. A pound indicates P,0.05 between WT and FXR-KO HFD group.
doi:10.1371/journal.pone.0035895.g005
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may at least be partially due to reduction of Sr-bi expression. Our
results also found that HFD induced hepatic Sr-bi expression
(Figure 6A) and this induction was, at least partially, by increasing
FXR binding to multiple IR1s in the first intron of the Sr-bi gene
(Figure 6B). Thus, the accumulation of HDL cholesterol in the
circulation of FXR-KO mice was at least partially due to the loss
of FXR regulation of Sr-bi expression. These combined findings
further established that FXR is a physiological modulator of SR-BI
which may enhance HDL reverse cholesterol transport. Thus,
induction of SR-BI by activation of FXR may help prevent
atherosclerosis. These findings, together with the recent finding
that FXR agonists protect against atherosclerosis [37,38,39],
suggest that FXR is a potential therapeutic target for maintaining
cholesterol homeostasis as well as for treatment of hypercholes-
terolemia and coronary heart disease.
In summary, the current study identified Sr-bi/SR-BI as a FXR
target gene in both mouse and human livers. The molecular
mechanism of FXR regulation of Sr-bi gene expression is via direct
binding of FXR to multiple novel FXRREs in the first intron of
the Sr-bi gene. Increased total and HDL cholesterol in FXR KO
mice may, at least partly, due to reduced Sr-bi expression.
Materials and Methods
Animals and treatments
WT and FXR-KO male mice in C57BL/6J genetic background
were used in this study (8–10 weeks old, n=4–6 per group). FXR-
KO mice have been backcrossed with C57BL/6J mice for over 10
Figure 6. FXR activation by HFD treatment increases Sr-bi expression by direct binding of FXR to multiple FXR binding sites in the
Sr-bi gene. A, Induction of Sr-bi mRNA expression in liver following treatment with vehicle or high fat-containing diet (HFD) in WT and FXR-KO mice,
as described in the Methods. Hepatic mRNA levels of Fxr, Shp, and Sr-bi were determined by Q-PCR. n=5 mice per group. An asterisk means P,0.05
between treatment and vehicle control group. B, ChIP-qPCR assays show binding of FXR to the first intron but not the downstream region containing
the novel IR1s in the Sr-bi gene in mouse livers after treatment with HFD. The relative intensity (fold) indicates fold increase over vehicle treatment
level. n=4 mice per group. An asterisk indicates P,0.05 between vehicle and HFD treatment group.
doi:10.1371/journal.pone.0035895.g006
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background. The VP-FXR transgenic mice were created by
over-expressing constitutively active FXR (VP-FXR) in the liver
and intestine using the tetracycline-inducible transgenic system.
The VP-FXR transgenic mice were DOX positive; therefore, the
DOX negative mice were used as controls. All mice were housed
in pathogen-free animal facilities under a standard 12-h light/dark
cycle with free access to food and autoclaved tap water. The
control and HFD were obtained from LabDiet (Olathe, KS) and
Jackson Laboratories (Bar Harbor, ME), respectively. The control
diet (5015) contained 17.8% protein, 64.8% carbohydrate, and
5.8% fat. The HFD (D12492) contained 26.2% protein, 26.3%
carbohydrate, and 34.9% saturated fat. The studies were carried
out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. All protocols and procedures were approved
by the University of Kansas Medical Center Animal Care and Use
Committee. The protocol number approved for these studies was
2010–1947.
To determine Sr-bi mRNA levels in liver by quantitative PCR
(qPCR), mice were fed with 1% (w/w) CA-containing diet or
regular diet for 5 days. The CA diet was made in house by mixing
CA (Sigma, St. Louis, MO) with regular wet rodent chow diet,
which was then completely dried. To determine Sr-bi mRNA
induction and FXR binding to the intron and downstream of the
Sr-bi gene by ChIP-qPCR, mice were orally gavaged with 75 mg/
kg GW4064 or vehicle twice (first dosage at 6 pm and second
dosage at 8 am next day) with livers harvested 4 hrs after the
second treatment. GW4064, which was synthesized by the
Chemical Discovery laboratory at the University of Kansas
(Lawrence, KS), was dissolved in vehicle (PBS containing 1%
methylcellulose and 1% Triton-100). For HFD feeding study, mice
were fed either a regular rodent chow or the HFD for 16 weeks. At
the end of the feeding, mice were subjected to fasting overnight
before tissue collection. Mouse livers were quickly removed, snap-
frozen in liquid nitrogen and stored at 280uC until use.
Cell culture
A human hepatocellular carcinoma cell line, HepG2, was
purchased from the American Type Culture Collection (Manassas,
VA). Primary human hepatocytes were obtained from the
University of Pittsburgh through the Liver Tissue Cell Distribution
System (NIH Contract #N01-DK-7-0004/HHSN26720070-
0004C). The primary human hepatocytes were obtained by
written consents from the participants. The research on primary
human hepatocytes has been approved by the institutional review
board in the University of Kansas Medical Center and University
of Pittsburgh. HepG2 cells were cultured in high-glucose DMEM
supplemented with 1% penicillin/streptomycin, 1% L-glutamine,
and 10% fetal bovine serum (Omega Scientific, Tarzana, CA).
Primary human hepatocyte culture was performed following
published methods [40]. All cells were maintained in 5% CO2
humidified atmosphere at 37uC. For treatment with bile acids
(CDCA, DCA, or LCA) or GW4064 in primary human
hepatocytes, the chemicals were dissolved in DMSO and diluted
to 10 mM, 30 mM, and 100 mM in cell culture medium before
treating cells for 48 hrs for measurement of gene expression.
HepG2 cells were also treated with 100 mM CDCA or 500 nM
GW4064 for 24 hrs for measurement of gene expression.
RNA isolation and quantitative real-time PCR (Q-PCR)
Total RNA was isolated from cells and frozen livers using Trizol
reagent (Sigma, Saint Louis, MO) according to the manufacturer’s
instructions. The concentration of total RNA was determined by
spectrophotometry with the integrity confirmed by MOPS gel
electrophoresis. The mRNA expression levels of FXR/Fxr, SHP/
Shp, SR-BI/Sr-bi, Cyp7a1, Ntcp, Ostb and Bsep were quantified by
Q-PCR using SYBR green chemistry (Fermentas, Glen Burnie,
MD) and normalized to GAPDH/Gapdh mRNA levels. The
primer sequences used in Q-PCR are presented in Table S1.
ChIP-Seq
ChIP-seq was performed as previously reported [17]. Histo-
grams of FXR binding to the Sr-bi gene in liver were generated
using Affymetrix Integrated Genome Browser [41].
ChIP-qPCR
ChIP-qPCR was performed on livers of mice treated with
vehicles, GW4064 or HFD following previously described
methods [17]. Briefly, fresh-frozen livers were minced and fixed
in 1% formaldehyde for 15 min and then quenched with 0.125 M
glycine. The cells were lysed and centrifuged. The nuclei pellet was
re-suspended in nuclear lysis buffer with protease inhibitors.
Nuclear extracts were sonicated to yield 500–1000 bp DNA
fragments. Sonicated chromatin was aliquoted and chromatin
(30 mg tissue equivalents) was used for each immunoprecipitation
assay. Samples were pre-cleared with Protein agarose G-salmon
sperm DNA beads (Millipore, Temecula, CA) before incubation
with an IgG antibody or anti-FXR antibody (H-130x) from Santa
Cruz Biotechnology (Santa Cruz, CA). Samples were incubated
with prepared protein agarose G-salmon sperm DNA beads in
order to extract antibody-chromatin complexes. Complexes were
washed and eluted with immunoprecipitation elution buffer. DNA
fragments associated with the FXR antibody were released by
incubating samples in a 450 mM NaCl solution at 65uC for 5 hrs.
RNA and protein were degraded by treating chromatin with
RNase A and proteinase K. DNA fragments were purified by
standard DNA column purification. The purified DNA fragments
that were bound by FXR were analyzed by qPCR with primers
amplifying four FXR binding sites located in the first intron and
the downstream region of the Sr-bi gene. The sequences for the
primers for ChIP-qPCR assay are presented in Table S1.
Construction of plasmids for reporter gene luciferase
assay
All three fragments, named as A, B and C, are located in the
first intron of the Sr-bi gene. Fragments A and B, each of which
contains a FXRRE in form of an IR1, are located from +10454 to
+11066 and +21265 to +21845 relative to the transcription start
site (TSS), respectively. Fragment C, containing two IR1s, is
located from +27508 to +28086 relative to the TSS. All fragments
were amplified from mouse genomic DNA by PCR using pairs of
primers containing XhoI and BglII restriction enzyme sites,
respectively (primer sequences are listed in Table S1). The PCR
products, named pGL10454, pGL21265 or pGL27508, were
subcloned upstream of the luciferase gene into pGL4-23 firefly
luciferase vector from Promega (Madison, WI). The sequences of
these constructs were confirmed by DNA sequencing and the new
plasmids were named as PGL4-23-Sr-bi A, PGL4-23-Sr-bi B, and
PGL4-23-Sr-bi C luciferase vector, respectively.
Construction of plasmids for Site-directed mutagenesis
of FXRREs
QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA) was used to generate mutations of the IR1 sites in
PGL4-23-Sr-bi A, PGL4-23-Sr-bi B, and PGL4-23-Sr-bi C,
according to the manufacturer’s instruction. Primers for site-
Farnesoid X Receptor Transactivates SR-BI
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were verified by DNA sequencing, and the mutated plasmids were
named as Mu-PGL4-23-Sr-bi A, Mu-PGL4-23-Sr-bi B, Mu-PGL4-
23-Sr-bi C-1
st IR1, Mu-PGL4-23-Sr-bi C-2
nd IR1 and Mu-PGL4-
23-Sr-bi C-(1
st+2
nd) IR1 luciferase vector, respectively.
Transient transfection and luciferase reporter gene assays
Briefly, HepG2 cells were seeded in a 96-well plate and grown
to 90% confluency prior to transient transfection with various
pGL4-23 reporter gene constructs as well as pCMV-ICIS human
FXR (Open Biosystems, Huntsville, AL), pSG5 human RXRa
(Stratagene, La Jolla, CA), and pCMV-renilla luciferase vector
(Promega, Madison, WI). Transient transfection was carried out
according to the manufacturer’s instructions using TurboFect in
vitro transfection reagent (Fermentas, Glen Burnie, MD). Five hrs
after transfection, cells were treated with 1 mM GW4064 or 0.1%
DMSO as negative control. Thirty-six hrs after treatment, firefly
luciferase and renilla luciferase activities were quantified using the
Dual-Glo Luciferase Kit (Promega, Madison, WI) in a Synergy-II
HT plate reader (Bio-Tek Instruments, Inc., Winooski, VT). The
firefly luciferase activity value was normalized as a ratio to that of
renilla luciferase and expressed as fold over the pGL4-23 empty
vector control. The data were presented as an average of six wells
and the experiments were repeated at least twice.
Determination of cholesterol levels in mouse serum and
livers
After WT and FXR-KO mice were fed either regular rodent
chow or HFD for 16 weeks, serum was obtained by centrifugation
of blood at 8,0006g using microtainer serum separator tubes (BD
Biosciences, San Jose, CA) for 15 min at 4uC and stored at 280uC
for analysis. Liver lipid content was also extracted as described
previously [42]. Briefly, 100 mg of frozen liver tissue was
homogenized in 1 ml of buffer containing 18 mM Tris, pH 7.5,
300 mM mannitol, 50 mM EGTA, and 0.1 mM phenylmethyl-
sulfonyl fluoride. Five hundred microliters of homogenate was
mixed with 4 ml of chloroform/methanol (2:1) and incubated
overnight at room temperature with occasional shaking. Subse-
quently, 1 ml of H2O was added and the solution was vortexed
and subjected to centrifugation for 5 minutes at 30006g. The
lower lipid phase was then collected and concentrated by vacuum.
The lipid pellets were dissolved in a mixture of 270 ml isopropanol
and 30 ml of Triton X-100. The kit for analyzing serum and liver
total cholesterol was obtained from Wako Bioproducts (Richmond,
VA). The kit for analyzing serum HDL, LDL/VLDL activity was
obtained from Abcam (Cambridge, MA). All measurements were
performed according to the manufacturer’s instructions.
Statistical analysis
All data were presented as mean 6 SD. All data were analyzed
by one-way analysis of variance followed by the Student-Newman-
Keuls test. P,0.05 was considered statistically significant.
Supporting Information
Figure S1 FXR activation in mouse livers by treatment
of FXR agonists or genetic over-expression of FXR. A,
Induction of FXR targets Cyp7a1, Ntcp, Ostb and Bsep mRNA levels
in the liver following treatment with either 1% cholic acid (CA)-
containing diet or GW4064 in WT and FXR-KO mice as
described in the Methods. An asterisk indicates P,0.05 and
double asterisks mean P,0.01 between vehicle and ligand
treatment group. B, Cyp7a1, Ntcp, Ostb and Bsep mRNA expression
levels in liver of FXR-WT and FXR-Tg mice. An asterisk means
P,0.05 and double asterisks indicate P,0.01 between FXR-WT
and FXR-Tg group.
(TIF)




The authors would like to thank Ms. Noriko Esterly and Lucy J. Lu for
their participation in the study.
Author Contributions
Conceived and designed the experiments: GLG GL. Performed the
experiments: GL AMT JAW BK JL YI WX. Analyzed the data: GL GLG
AMT. Contributed reagents/materials/analysis tools: YI WX. Wrote the
paper: GLG GL.
References
1. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, et al. (2000) Targeted
disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid
homeostasis. Cell 102: 731–744.
2. Kok T, Hulzebos CV, Wolters H, Havinga R, Agellon LB, et al. (2003)
Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice:
efficient intestinal bile salt absorption in the absence of ileal bile acid-binding
protein. J Biol Chem 278: 41930–41937.
3. Kalaany NY, Mangelsdorf DJ (2006) LXRS and FXR: the yin and yang of
cholesterol and fat metabolism. Annu Rev Physiol 68: 159–191.
4. Lambert G, Amar MJ, Guo G, Brewer HB, Jr., Gonzalez FJ, et al. (2003) The
farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol
Chem 278: 2563–2570.
5. Gadaleta RM, van Mil SW, Oldenburg B, Siersema PD, Klomp LW, et al.
(2010) Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary
and gastrointestinal disease. Biochim Biophys Acta 1801: 683–692.
6. Zhu Y, Li F, Guo GL (2011) Tissue-specific function of farnesoid X receptor in
liver and intestine. Pharmacol Res 63: 259–265.
7. Acton SL, Scherer PE, Lodish HF, Krieger M (1994) Expression cloning of SR-
BI, a CD36-related class B scavenger receptor. J Biol Chem 269: 21003–21009.
8. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, et al. (1996)
Identification of scavenger receptor SR-BI as a high density lipoprotein
receptor. Science 271: 518–520.
9. Landschulz KT, Pathak RK, Rigotti A, Krieger M, Hobbs HH (1996)
Regulation of scavenger receptor, class B, type I, a high density lipoprotein
receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 98: 984–995.
10. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, et al. (1997)
Overexpression of the HDL receptor SR-BI alters plasma HDL and bile
cholesterol levels. Nature 387: 414–417.
11. Wang N, Arai T, Ji Y, Rinninger F, Tall AR (1998) Liver-specific overexpression
of scavenger receptor BI decreases levels of very low density lipoprotein ApoB,
low density lipoprotein ApoB, and high density lipoprotein in transgenic mice.
J Biol Chem 273: 32920–32926.
12. Krieger M (1999) Charting the fate of the ‘‘good cholesterol’’: identification and
characterization of the high-density lipoprotein receptor SR-BI. Annu Rev
Biochem 68: 523–558.
13. Zhang Y, Yin L, Anderson J, Ma H, Gonzalez FJ, et al. (2010) Identification of
novel pathways that control farnesoid X receptor-mediated hypocholesterol-
emia. J Biol Chem 285: 3035–3043.
14. Chao F, Gong W, Zheng Y, Li Y, Huang G, et al. (2010) Upregulation of
scavenger receptor class B type I expression by activation of FXR in hepatocyte.
Atherosclerosis 213: 443–448.
15. Li G, Thomas AM, Hart SN, Zhong X, Wu D, et al. (2010) Farnesoid X
receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene
encoding small heterodimer partner. Mol Endocrinol 24: 1404–1412.
16. Teodoro JS, Rolo AP, Palmeira CM (2011) Hepatic FXR: key regulator of
whole-body energy metabolism. Trends Endocrinol Metab 22: 458–466.
17. Thomas AM, Hart SN, Kong B, Fang J, Zhong XB, et al. (2010) Genome-wide
tissue-specific farnesoid X receptor binding in mouse liver and intestine.
Hepatology 51: 1410–1419.
18. Fuchs M, Ivandic B, Muller O, Schalla C, Scheibner J, et al. (2001) Biliary
cholesterol hypersecretion in gallstone-susceptible mice is associated with hepatic
Farnesoid X Receptor Transactivates SR-BI
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35895up-regulation of the high-density lipoprotein receptor SRBI. Hepatology 33:
1451–1459.
19. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, et al. (2006) Activation of the
nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic
mice. Proc Natl Acad Sci U S A 103: 1006–1011.
20. Malerod L, Sporstol M, Juvet LK, Mousavi SA, Gjoen T, et al. (2005) Bile acids
reduce SR-BI expression in hepatocytes by a pathway involving FXR/RXR,
SHP, and LRH-1. Biochem Biophys Res Commun 336: 1096–1105.
21. Park PJ (2009) ChIP-seq: advantages and challenges of a maturing technology.
Nat Rev Genet 10: 669–680.
22. Farnham PJ (2009) Insights from genomic profiling of transcription factors. Nat
Rev Genet 10: 605–616.
23. Hawkins RD, Hon GC, Ren B (2010) Next-generation genomics: an integrative
approach. Nat Rev Genet 11: 476–486.
24. Gao H, Falt S, Sandelin A, Gustafsson JA, Dahlman-Wright K (2008) Genome-
wide identification of estrogen receptor alpha-binding sites in mouse liver. Mol
Endocrinol 22: 10–22.
25. Hamza MS, Pott S, Vega VB, Thomsen JS, Kandhadayar GS, et al. (2009) De-
novo identification of PPARgamma/RXR binding sites and direct targets
during adipogenesis. PLoS One 4: e4907.
26. Chong HK, Infante AM, Seo YK, Jeon TI, Zhang Y, et al. (2010) Genome-wide
interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy
with LRH-1. Nucleic Acids Res 38: 6007–6017.
27. Lopez D, McLean MP (2006) Activation of the rat scavenger receptor class B
type I gene by PPARalpha. Mol Cell Endocrinol 251: 67–77.
28. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, et al. (2003) Bile
acids induce the expression of the human peroxisome proliferator-activated
receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol
17: 259–272.
29. Mardones P, Pilon A, Bouly M, Duran D, Nishimoto T, et al. (2003) Fibrates
down-regulate hepatic scavenger receptor class B type I protein expression in
mice. J Biol Chem 278: 7884–7890.
30. Malerod L, Juvet LK, Hanssen-Bauer A, Eskild W, Berg T (2002) Oxysterol-
activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells
and preadipocytes. Biochem Biophys Res Commun 299: 916–923.
31. Schoonjans K, Annicotte JS, Huby T, Botrugno OA, Fayard E, et al. (2002)
Liver receptor homolog 1 controls the expression of the scavenger receptor class
B type I. EMBO Rep 3: 1181–1187.
32. Malerod L, Sporstol M, Juvet LK, Mousavi A, Gjoen T, et al. (2003) Hepatic
scavenger receptor class B, type I is stimulated by peroxisome proliferator-
activated receptor gamma and hepatocyte nuclear factor 4alpha. Biochem
Biophys Res Commun 305: 557–565.
33. Ahmed RA, Murao K, Imachi H, Yu X, Li J, et al. (2009) Human scavenger
receptor class B type 1 is regulated by activators of peroxisome proliferators-
activated receptor-gamma in hepatocytes. Endocrine 35: 233–242.
34. Al-Jarallah A, Trigatti BL (2010) A role for the scavenger receptor, class B type I
in high density lipoprotein dependent activation of cellular signaling pathways.
Biochim Biophys Acta 1801: 1239–1248.
35. Ueda Y, Royer L, Gong E, Zhang J, Cooper PN, et al. (1999) Lower plasma
levels and accelerated clearance of high density lipoprotein (HDL) and non-
HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol
Chem 274: 7165–7171.
36. Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, et al. (2003)
Differential effects of scavenger receptor BI deficiency on lipid metabolism in
cells of the arterial wall and in the liver. J Biol Chem 278: 23699–23705.
37. Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, et al. (2009) Discovery of
XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the
farnesoid X receptor (FXR). J Med Chem 52: 904–907.
38. Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, et al. (2009)
Activation of farnesoid X receptor prevents atherosclerotic lesion formation in
LDLR2/2 and apoE2/2 mice. J Lipid Res 50: 1090–1100.
39. Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009) Antiatherosclerotic effect
of farnesoid X receptor. Am J Physiol Heart Circ Physiol 296: H272–281.
40. Han S, Li T, Ellis E, Strom S, Chiang JY (2010) A novel bile acid-activated
vitamin D receptor signaling in human hepatocytes. Mol Endocrinol 24:
1151–1164.
41. Nicol JW, Helt GA, Blanchard SG, Jr., Raja A, Loraine AE (2009) The
Integrated Genome Browser: free software for distribution and exploration of
genome-scale datasets. Bioinformatics 25: 2730–2731.
42. Tanaka Y, Aleksunes LM, Yeager RL, Gyamfi MA, Esterly N, et al. (2008) NF-
E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a
high-fat diet. J Pharmacol Exp Ther 325: 655–664.
Farnesoid X Receptor Transactivates SR-BI
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35895